Apex Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Apex Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	$4.27M	Sell	11,855 -1,459	-11%	-$601K	0.09%	158
2015 Q4	$7.23M	Buy	13,314 +387	+3%	+$210K	0.16%	127
2015 Q3	$6.01M	Buy	12,927 +3,763	+41%	+$2.02M	0.14%	132
2015 Q2	$4.67M	Sell	9,164 -91	-1%	-$44.4K	0.1%	154
2015 Q1	$4.18M	Sell	9,255 -740	-7%	-$314K	0.1%	162
2014 Q4	$4.1M	Sell	9,995 -118	-1%	-$46.4K	0.11%	153
2014 Q3	$3.65M	Buy	10,113 +947	+10%	+$317K	0.11%	149
2014 Q2	$2.59M	Sell	9,166 -359	-4%	-$106K	0.08%	168
2014 Q1	$2.86M	Buy	9,525 +73	+0.8%	+$22.5K	0.1%	157
2013 Q4	$2.6M	Buy	9,452 +579	+7%	+$167K	0.1%	149
2013 Q3	$2.78M	Buy	+8,873	New	+$2.33M	0.12%	132

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Apex Capital Management's REGN Position: Q1 2016 in Review

Apex Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2016, selling an estimated $601K and leaving 11,855 shares worth $4.27M. The position accounts for 0.09% of the portfolio, ranked #158.

Apex Capital Management first reported a position in REGN in Q3 2013 and has held it in 11 quarters since. The position peaked at $7.23M in Q4 2015. 549 funds tracked by Wall St. Rank hold REGN as of Q1 2016.

Apex Capital Management held 11,855 shares of Regeneron Pharmaceuticals worth $4.27M as of Q1 2016.
Apex Capital Management sold 1,459 Regeneron Pharmaceuticals shares in Q1 2016, an estimated $601K.
Regeneron Pharmaceuticals made up 0.09% of Apex Capital Management's portfolio in Q1 2016, its #158 holding.
Apex Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 11 quarters since.
Apex Capital Management's Regeneron Pharmaceuticals position peaked at $7.23M in Q4 2015.
549 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2016.

Based on Apex Capital Management's 13F filing for Q1 2016, filed 27 Apr 2016.